Novartis Ag (NVS) Revenue Growth (3y) (2012 - 2026)
Novartis Ag (NVS) Revenue Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.56% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 7.01% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.37% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 8.00% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 10.45% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.90% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 5.75% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 62.71% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 7.90% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 7.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.00% |
| Mar 31, 2026 | 0.21% |
| Dec 31, 2025 | -75.31% |
| Sep 30, 2025 | 19.63% |
| Jun 30, 2025 | 3.22% |
| Mar 31, 2025 | -21.36% |
| Dec 31, 2024 | -1.37% |
| Jun 30, 2024 | -1.16% |
| Mar 31, 2024 | -34.85% |
| Dec 31, 2023 | -2.01% |
| Sep 30, 2023 | -22.45% |
| Jun 30, 2023 | 0.26% |
| Mar 31, 2023 | 10.67% |
| Dec 31, 2022 | 401.24% |
| Sep 30, 2022 | 42.18% |
| Jun 30, 2022 | 2.80% |
| Mar 31, 2022 | 3.03% |
| Dec 31, 2021 | 380.96% |
| Sep 30, 2021 | -28.57% |
| Jun 30, 2021 | 4.48% |